Study Summary
This trial is studying the best dose of temozolomide to give with niraparib and atezolizumab to treat patients with advanced solid tumors and extensive-stage small cell lung cancer.
- Stage IVB Lung Cancer AJCC v8
- Malignant Neoplasms
- Small cell carcinoma of lung
- Stage IIIC Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Advance Directives
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 3 Secondary · Reporting Duration: Up to 36 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm B (atezolizumab)
1 of 2
Arm A (temozolomide, niraparib, atezolizumab)
1 of 2
Active Control
Experimental Treatment
74 Total Participants · 2 Treatment Groups
Primary Treatment: Quality-of-Life Assessment · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 6th, 2021
Last Reviewed: November 12th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.